FORM 51-102F3 Material Change Report

ITEM 1 Name and Address of Company

HAVN Life Sciences Inc. (the "**Company**") Unit 100 – 22071 Fraserwood Way Richmond, BC V6W 1J5

ITEM 2 Date of Material Change

January 5, 2022

ITEM 3 <u>News Release</u>

A news release announcing the material change was disseminated on January 5, 2022 and subsequently filed on SEDAR.

ITEM 4 <u>Summary of Material Changes</u>

On January 5, 2022, the Company announced the appointment of Mr. Gary Leong to its Board of Directors. Concurrently, Mr. Leong stepped down as the Company's Chief Science Officer.

ITEM 5 Full Description of Material Change

On January 5, 2022, the Company announced the appointment of Mr. Gary Leong to its Board of Directors. Concurrently, Mr. Leong stepped down as the Company's Chief Science Officer, shifting his focus to an advisory role within the Company.

Mr. Leong has been instrumental in the regulatory development and launch of the Company's Retail Division, formulating its portfolio of natural health products, launched in June of 2021. Gary Leong has more than thirty years of experience in the pharmaceutical and natural health product industries. Mr. Leong is currently acting as the Director of Quality and Compliance at the privately Licensed Cannabis Processor, Tricanna Industries Inc. He was the Chief Scientific Officer at Aphria Inc. in Leamington, ON from its inception in 2014 to 2019, where he established and oversaw the Quality Assurance, Quality Control, Regulatory Affairs and Research and Development functions. Prior to this, he served as the Chief Scientific Officer of Jamieson Laboratories in Windsor, ON for fourteen years. He has also managed the scientific and quality functions for Boehringer Ingelheim, Natural Factors Nutritional Products Ltd. and Nordion. Gary holds a B.Sc. in Chemistry and a M.B.A. in Quality Management and has served on the Board of Directors of several public companies and research societies, as well as an advisor to several Canadian government regulatory advisory committees.

ITEM 6 Reliance on Subsection 7.1(2) of National Instrument 51-102

Not applicable.

ITEM 7 <u>Omitted Information</u>

No information has been omitted on the basis that it is confidential information.

ITEM 8 <u>Executive Officer</u>

For further information, please contact Tim Moore, Chief Executive Officer of the Company, at 604-359-0060.

ITEM 9 Date of Report

January 10, 2022